Special Issue "Antifungal Combinations in Fungal Infections"
A special issue of Journal of Fungi (ISSN 2309-608X).
Deadline for manuscript submissions: 31 July 2021.
Interests: antifungals; antifungal combinations; fungal diagnostics; medical mycology
Interests: human pathogenic fungi; antifungals; mycoses; aspergillus; in vitro susceptibility testing; antifungal resistance; animal models
Special Issues and Collections in MDPI journals
Special Issue in Journal of Fungi: Antifungal Agents Recently Approved or Under Development
Many fungal infections are difficult to treat, in part because of the intrinsic or acquired resistance of many fungi to currently available antifungal drugs. Antifungal combinations are an interesting tool, not only to overcome this resistance, but also because of the potential synergism obtained, when drugs are acting together. Various methods of assessing antifungal combinations have been used. In vitro, most often used is the checkerboard method based on the EUCAST or CLSI microdilution broth reference techniques. Usually interpreted by the fractional inhibitory concentration index, other ways of analysis and interpretation of the results have also beeing used, as no standardized procedures have been estabilished. The gold standard for assessing antifungal combinations in vivo are survival models in mammals, but fungal burden studies have also been used successfully, and alternative minihost models have been implemented. Indeed, because of ethical reasons, in recent years animal models in invertebrates like the waxmoth Galleria mellonella have become more and more popular. A success story for antifungal combinations has become the combination of amphotericin B with flucytonsine, which is recommended first-line treament for patients with cryptococcosis. For other fungal pathogens (e.g. Candida spp., Aspergillus spp., rare molds), combination therapy are generally not recommend as first-line but can be of interest for species with intrisic or acquired resistance. In view of the fact that drug repurposing has major advantages like the use of de-risked compounds, with potentially lower overall development costs and shorter development timelines, combinations of antifungals with non-antifungal drugs have also become atractive.
In this Special Issue several reviews will address the current status of antifungal combinations against fungi of medical importance. Original works are also wellcome.
Dr. Patrick Schwarz
Dr. Eric Dannaoui
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Antifungal agents
- Drug therapy, Combination
- In vitro susceptibility testing
- Animal models
- Human fungal pathogens
- Filamentous fungi
- Fractional Inhibitory Concentration Index (FIC index)
- Response surface analysis
- Drug synergism
- Loewe Additivity
- Bliss Independence